Smiths Medical has received FDA 510(k) clearance to market its CADD-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the US.
The new state-of-the-art pain management system is easy to use and provides improved pain management. This customized system meets industry recognized standards for advanced error-reduction features in PCA pumps.
Epidural analgesia has traditionally been provided to patients using a pump that delivers manual bolus injections from a clinician, continuous infusions, or intermittent doses of medication controlled by the patient.
However,these techniques can result in inconsistent and/or ineffective pain relief, as well as frequent clinician interventions.
PIB medication delivery, using the CADD-Solis v3.0 system, consistently administers programmed intermittent boluses that can be supplemented by patient-controlled doses.
Smiths Medical vice president global product management Tommy Johns said the new CADD-Solis system with PIB and PCA combines programmed intermittent boluses and patient-controlled doses in an integrated, innovative delivery system.
"The PIB programming parameters and the delivery pressure provided by the CADD-Solis system offer flexible drug delivery and reliable distribution of medication, which can help overcome some of the challenges associated with epidural analgesia," Johns added.
The system is designed to help healthcare professionals administer medication accurately, monitor a patient’s response to therapy, stimulate early clinical assessment and facilitate patient recovery.
The system’s compact lightweight design promotes patient mobility, which is associated with improved clinical outcomes, reduced length of stay and reduced treatment costs.
Image: Smiths Medical receives FDA 510(k) clearance on solution for pain management with CADD-Solis pump. Photo: Courtesy of Smiths Medical.